Difference in incidence of cough induced by imidapril and ramipril: Role of prostaglandin synthesis inhibition

Roberto Fogari, Annalisa Zoppi, Amedeo Mugellini, Maurizio Destro, Pierangelo Lazzari, Giuseppe Derosa

Research output: Contribution to journalArticle

Abstract

Aim of this study was to evaluate whether treatment with imidapril reduced cough induced by ramipril. The effect of adding indomethacin, a known inhibitor of prostaglandin (PG) synthesis, to the two ACE-inhibitors (ACE-I) on cough frequency and intensity was also assessed. After a 2-week placebo period, 97 hypertensive patients who developed cough during ramipril treatment were randomized to ramipril 10 mg or imidapril 20 mg for 8 weeks. Thereafter, patients still complaining cough continued the respective ACE-inhibitor treatment, but in each arm they were allocated to receive also indomethacin 50 mg or placebo for 4 weeks according to a double-blind, cross-over design. At the end of each phase of the study cough was assessed by means of a self-administered questionnaire with an ordinal 10-point visual analogue scale for rating daily cough intensity and frequency. At the end of the 8-week monotherapy phase, cough was complained by 48 of 49 (98%) patients randomized to ramipril and by 24 of the 48 (50%) patients randomized to imidapril, the difference between the two groups being significant (P <0.01). Indomethacin significantly reduced the mean score for cough intensity and frequency (P <0.01) in both ramipril and imidapril treated patients, with no difference between the two groups. These results indicate that the incidence of cough recurrence is lower with imidapril than with ramipril. The finding that the effect of indomethacin on cough frequency and intensity is the same in the two treatment groups suggests that the lower incidence of cough observed with imidapril might be mediated by some mechanism independent of PG synthesis.

Original languageEnglish
Pages (from-to)73-77
Number of pages5
JournalBiomedicine and Aging Pathology
Volume1
Issue number2
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Ramipril
Cough
Prostaglandins
Incidence
Indomethacin
Angiotensin-Converting Enzyme Inhibitors
imidapril
Placebos
Prostaglandin Antagonists
Therapeutics
Visual Analog Scale
Cross-Over Studies

Keywords

  • Cough
  • Imidapril
  • Ramipril

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pathology and Forensic Medicine
  • Ageing

Cite this

Difference in incidence of cough induced by imidapril and ramipril : Role of prostaglandin synthesis inhibition. / Fogari, Roberto; Zoppi, Annalisa; Mugellini, Amedeo; Destro, Maurizio; Lazzari, Pierangelo; Derosa, Giuseppe.

In: Biomedicine and Aging Pathology, Vol. 1, No. 2, 04.2011, p. 73-77.

Research output: Contribution to journalArticle

@article{f0ffcfdf3cf34360ad352b7540692258,
title = "Difference in incidence of cough induced by imidapril and ramipril: Role of prostaglandin synthesis inhibition",
abstract = "Aim of this study was to evaluate whether treatment with imidapril reduced cough induced by ramipril. The effect of adding indomethacin, a known inhibitor of prostaglandin (PG) synthesis, to the two ACE-inhibitors (ACE-I) on cough frequency and intensity was also assessed. After a 2-week placebo period, 97 hypertensive patients who developed cough during ramipril treatment were randomized to ramipril 10 mg or imidapril 20 mg for 8 weeks. Thereafter, patients still complaining cough continued the respective ACE-inhibitor treatment, but in each arm they were allocated to receive also indomethacin 50 mg or placebo for 4 weeks according to a double-blind, cross-over design. At the end of each phase of the study cough was assessed by means of a self-administered questionnaire with an ordinal 10-point visual analogue scale for rating daily cough intensity and frequency. At the end of the 8-week monotherapy phase, cough was complained by 48 of 49 (98{\%}) patients randomized to ramipril and by 24 of the 48 (50{\%}) patients randomized to imidapril, the difference between the two groups being significant (P <0.01). Indomethacin significantly reduced the mean score for cough intensity and frequency (P <0.01) in both ramipril and imidapril treated patients, with no difference between the two groups. These results indicate that the incidence of cough recurrence is lower with imidapril than with ramipril. The finding that the effect of indomethacin on cough frequency and intensity is the same in the two treatment groups suggests that the lower incidence of cough observed with imidapril might be mediated by some mechanism independent of PG synthesis.",
keywords = "Cough, Imidapril, Ramipril",
author = "Roberto Fogari and Annalisa Zoppi and Amedeo Mugellini and Maurizio Destro and Pierangelo Lazzari and Giuseppe Derosa",
year = "2011",
month = "4",
doi = "10.1016/j.biomag.2011.01.001",
language = "English",
volume = "1",
pages = "73--77",
journal = "Biomedicine and Aging Pathology",
issn = "2210-5220",
publisher = "Elsevier Masson",
number = "2",

}

TY - JOUR

T1 - Difference in incidence of cough induced by imidapril and ramipril

T2 - Role of prostaglandin synthesis inhibition

AU - Fogari, Roberto

AU - Zoppi, Annalisa

AU - Mugellini, Amedeo

AU - Destro, Maurizio

AU - Lazzari, Pierangelo

AU - Derosa, Giuseppe

PY - 2011/4

Y1 - 2011/4

N2 - Aim of this study was to evaluate whether treatment with imidapril reduced cough induced by ramipril. The effect of adding indomethacin, a known inhibitor of prostaglandin (PG) synthesis, to the two ACE-inhibitors (ACE-I) on cough frequency and intensity was also assessed. After a 2-week placebo period, 97 hypertensive patients who developed cough during ramipril treatment were randomized to ramipril 10 mg or imidapril 20 mg for 8 weeks. Thereafter, patients still complaining cough continued the respective ACE-inhibitor treatment, but in each arm they were allocated to receive also indomethacin 50 mg or placebo for 4 weeks according to a double-blind, cross-over design. At the end of each phase of the study cough was assessed by means of a self-administered questionnaire with an ordinal 10-point visual analogue scale for rating daily cough intensity and frequency. At the end of the 8-week monotherapy phase, cough was complained by 48 of 49 (98%) patients randomized to ramipril and by 24 of the 48 (50%) patients randomized to imidapril, the difference between the two groups being significant (P <0.01). Indomethacin significantly reduced the mean score for cough intensity and frequency (P <0.01) in both ramipril and imidapril treated patients, with no difference between the two groups. These results indicate that the incidence of cough recurrence is lower with imidapril than with ramipril. The finding that the effect of indomethacin on cough frequency and intensity is the same in the two treatment groups suggests that the lower incidence of cough observed with imidapril might be mediated by some mechanism independent of PG synthesis.

AB - Aim of this study was to evaluate whether treatment with imidapril reduced cough induced by ramipril. The effect of adding indomethacin, a known inhibitor of prostaglandin (PG) synthesis, to the two ACE-inhibitors (ACE-I) on cough frequency and intensity was also assessed. After a 2-week placebo period, 97 hypertensive patients who developed cough during ramipril treatment were randomized to ramipril 10 mg or imidapril 20 mg for 8 weeks. Thereafter, patients still complaining cough continued the respective ACE-inhibitor treatment, but in each arm they were allocated to receive also indomethacin 50 mg or placebo for 4 weeks according to a double-blind, cross-over design. At the end of each phase of the study cough was assessed by means of a self-administered questionnaire with an ordinal 10-point visual analogue scale for rating daily cough intensity and frequency. At the end of the 8-week monotherapy phase, cough was complained by 48 of 49 (98%) patients randomized to ramipril and by 24 of the 48 (50%) patients randomized to imidapril, the difference between the two groups being significant (P <0.01). Indomethacin significantly reduced the mean score for cough intensity and frequency (P <0.01) in both ramipril and imidapril treated patients, with no difference between the two groups. These results indicate that the incidence of cough recurrence is lower with imidapril than with ramipril. The finding that the effect of indomethacin on cough frequency and intensity is the same in the two treatment groups suggests that the lower incidence of cough observed with imidapril might be mediated by some mechanism independent of PG synthesis.

KW - Cough

KW - Imidapril

KW - Ramipril

UR - http://www.scopus.com/inward/record.url?scp=80053895786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053895786&partnerID=8YFLogxK

U2 - 10.1016/j.biomag.2011.01.001

DO - 10.1016/j.biomag.2011.01.001

M3 - Article

AN - SCOPUS:80053895786

VL - 1

SP - 73

EP - 77

JO - Biomedicine and Aging Pathology

JF - Biomedicine and Aging Pathology

SN - 2210-5220

IS - 2

ER -